Career Enhancement Program

项目总结 淋巴瘤孢子职业提升计划的目标是为年轻人提供支持 致力于转译淋巴瘤研究的研究人员以及成熟的研究人员 希望重新将工作重点放在淋巴瘤上。该项目由海伦·海斯洛普博士、玛莎·米姆斯博士和希德博士领导。 将由行政核心在执行委员会的监督下进行协调 以及内部和外部咨询委员会。在之前的资金周期中不断改进，我们的 既定的职业提升计划有明确的招聘流程和候选人招聘流程。我们会 继续与贝勒多元化、公平和包容性办公室合作，致力于 招募妇女和少数族裔加入我们的方案和淋巴瘤研究领域--这项倡议一直是 在过去的供资期间取得成功，当时53%的受训人员是女性，37%的受训人员任职人数不足 少数族裔(西班牙裔或非裔美国人)。医学博士和博士实习生都可以利用这些课程 通过贝勒医学院的临床科学家培训计划提供，并将有强大的 一组具有广泛翻译专业知识的导师。我们已经制定了指导策略，专注于 将细胞和基因疗法从长椅移到床边的独特挑战以及动态 团队科学，这加强了整体训练计划。具体而言，这些战略包括提供 拥有多名导师的学员，这些导师拥有互补的技能、个性化的培训计划和多个 有机会参加与该领域相关的学习课程和讲座。此外，受训人员 获得孢子核心(临床研究和生物统计学、细胞处理和病媒生产、 生物医学和病理学)，在细胞和基因治疗以及临床研究方面拥有独特的专长。在最后一次 14年来，19名获奖者被评为该计划的获奖者，其中7人现在被纳入 孢子计划与4名项目负责人在目前的更新。因此，该计划将确保 孢子将继续培训有前途的研究人员，他们将为翻译淋巴瘤研究做出贡献 通向未来。

PROJECT SUMMARY The goal of the Lymphoma SPORE’s Career Enhancement Program is to provide support for young investigators pursuing careers in translational lymphoma research as well as for established investigators who wish to refocus their work on lymphoma. The program is led by Drs. Helen Heslop, Martha Mims and Sid Ganguly and will be co-ordinated by the Administrative Core with oversight from the Executive Committee and Internal and External Advisory Boards. Continually improved throughout the previous funding cycles, our established Career Enhancement Program has well-defined processes and for candidate recruitment. We will continue to collaborate with the Baylor Office of Diveristy, Equity, and Inclusion to devote significant effort to recruit women and minorities to our program and the field of lymphoma research — an initiative that has been successful in the past funding periods when 53% of trainees were female and 37% were under-represented minorities (Hispanic or African American). Both MD and PhD trainees will be able to take advantage of courses available through the Clinical Scientist Training Program at Baylor College of Medicine and will have a strong group of mentors with broad translational expertise. We have developed mentoring strategies focued on the unique challenges of moving cell and gene therapies from the bench-to-the-bedside, as well as the dynamics of team science, that enhance the overall training program. Specifically, these strategies include providing trainees with multiple mentors that possess complementary skills, individualized training plans, and multiple opportunities to participate in learning courses and attend lectures relevant to the field. Additionally, trainees have access to the SPORE cores (Clinical Research and Biostatistics, Cell Processing and Vector Production, Biospecimen and Pathology) with unique expertise in cell and gene therapy and clinical research. In the last 14 years,19 awardees have been selected for this Program, seven of whom are now incorporated into the SPORE program with 4 as project leaders in the current renewal . This Program will therefore ensure that the SPORE will continue to train promising investigators who will contribute to translational lymphoma research into the future.